Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Inclusion Criteria: * The participant and/or their parent/Legally Authorized Representative is willing and able to provide signed informed consent or assent as appropriate * Male or female adults 18 to 80 years of age, or adolescents 12 to 17 years of age * Patients dependent on parenteral nutrition (PN) that receive PN for an average ≥ 4 days a week for 10 weeks or longer prior to screening to meet nutritional, caloric, fluid, and/or electrolyte needs * The Investigator expects no changes in the lipid, dextrose, amino acid, or vitamin regimen to be medically necessary during the participant's participation in the study * Willingness of participant to maintain his/her current habitual oral diet and fluids regimen for the study duration Exclusion Criteria: * Participants taking steatogenic medications for ≥12 weeks in the past 12 months (e.g., amiodarone, tamoxifen, methotrexate, tetracycline, glucocorticoids, anabolic steroids, over the usual dose of estrogen for hormone replacement therapy, and valproate); those taking any medicine (e.g., metformin, thiazolidinediones, ursodeoxycholic acid, pentoxifylline, S-adenosyl-L-Methionine, and betaine) that could affect the measurement of IFALD within 12 weeks prior to study entry * Participants taking potential hepatotoxic medications that in the judgement of the Investigator is causing hepatic abnormalities * Participants with a cardiac pacemaker, intravascular stents, other metallic devices, and claustrophobia which are contraindicated to magnetic resonance imaging * Participants who took choline supplements or choline-containing multivitamins within 14 days of screening * History of major organ transplant (e.g., heart, kidney, liver, etc.) For more information on eligibility criteria, please contact the sponsor.